Hbl- Hadasit Bio-holdings Ltd. · TASE:HDST-M
Hbl- Hadasit Bio-holdings — Hadasit Bio-Holdings — Investor Presentation (January 2013)
24 slides from Hbl- Hadasit Bio-holdings's investor presentation, January 2013
Slide 1: Corporate presentation
www.hbl.co.il Corporate presentation Hadasit Bio-Holdings Ltd. (“HBL”) (TASE: HDST) (OTC BB: HADSY)
Slide 2: Forward Looking Statements
Forward Looking Statements This document/presentation contains forward looking statements. Words such as “estimates,” “expects,” “intends,” “plans,” “believes” and terms of similar substance used in connection with any discussion of future operational performance or financial results, identify forwa
Slide 3: Introduction
Introduction Hadassah is a leading source of scientific and medical innovation A portfolio of start-up companies was established based on these new drugs and devices Hadassah founded a holding company to manage these companies and finance them through the public markets The holding company, Hada
Slide 4: About Us
About Us Hadasit Bio-Holdings (HBL) was founded to: Help finance biotechnology innovation flowing from the Hadassah Medical Center Allow investors unique opportunities to invest in resulting attractive products • Established: September 2005 • Publicly Traded: Tel Aviv Stock Exchange (HDST), since
Slide 5: Crossing the Valley of Death
The Modern Day Leap of Faith Crossing the “Valley of Death” Early stage Phase II/III Clinical Trials $50k - $0.5mm +$20mm Academia, VCs, Angels, 3F’s Corporate, Institutional, Strategic Partners How can we bridge the gap?
Slide 6: About Us (Cont.)
About Us (Cont.) Set up as a financial arm and holding company Raised ~$25 M from public markets in order to invest in the companies based on Hadassah IP and innovation Funds support researchers and physicians in Hadassah Our goal: • Protect Hadassah holdings from dilution by aggressive investor
Slide 7: Hadassah Medical Organization
Hadassah Medical Organization: 2 University Hospitals; Affiliated with Heb. U. Ein Kerem: 880 beds Mount Scopus: 330 beds Leveraging Hadassah Hospital: Skilled personnel, infrastructure, GMP facilities, financing, Bio- Park, and clinical trials facilities R&D Excellence: 52% of all translational res
Slide 8: Corporate Structure
Corporate Structure Hadassah 100% Public CBG* 35% 56% 9% 65% 56% 70% 13% 92% 21% * Consensus Business Group – UK Private Equity 7
Slide 9: Investment Highlights
Investment Highlights Diversified portfolio - HBL owns a significant stake in 6 different promising biotech companies All portfolio companies have demonstrated proof-of-concept and operate in a blockbuster market, most already in clinical stages HBL recruited major strategic partners for inves
Slide 10: Unique Added Value & Positioning
Unique Added Value & Positioning Clinical Hadasit Scientific Bio-Holdings Pharmaceutical Companies Contribution Infrastructure Incubators Business & Bio VC Fund Bio VC Financial Dev. Gov Fund VC FFF/ & Fund Financial AcademiaIncubators Phase I Phase II Seed Market Phase Clinical Pre Stage III 10
Slide 11: Focus - Risk Vs. Return
Focus - Risk Vs. Return • Where do we add value, utilize resources and reduce risk? Proof of Pre-Clinical Phase I Phase II Phase III Approval Concept Success Rate, per phase Percent of total investment Required investment $m Years • Big Pharma companies are losing income due to patent expiration (ge
Slide 12: Recent Achievements and PR
Recent Achievements and PR • Jan. 22, 2013 – ProtAb and Enlivex Receive Funding to Support Clinical Trial Preparations and Obtain Regulatory Approvals in U.S. and Europe • Nov. 11, 2012 - CellCure Receives Additional Financing From BioTime Inc. • Oct. 16, 2012 - Company’s ADR - HADSY - Now Blue Sky
Slide 13: Hadasit Bio-Holdings: Added Value = I3
Hadasit Bio-Holdings : Added Value = I3 Innovation Investments Infrastructure • University Hospital • IPO • Jerusalem Bio-Park • 6 Teaching Faculties • Bond Financing • 6 fl., 10,000 ft.2 • 52% of Trans. Res. • PIPE X 2 • GMP Facility • 50 Patent Families • Rights Issuance • Animal Facility • 12 spu
Slide 14: Portfolio by Market Size
Portfolio by Market Size Company Field/Treating Market Size D-Pharm Stroke, Myocardial Infarction, Alzheimer's Stroke: $ 500 million Cardiac Arrest: $ 1 billion KAHR Medical Cancer, Inflammatory Diseases Cancer + Autoimmune diseases: $ 5 billion ProtAb Inflammatory and Autoimmune Disease RA: $ 18 bi
Slide 15: Portfolio by Development Stage
Portfolio by Development Stage HBL Portfolio Company Disease Area HBLLead Opt. Animal Preclinical Phase I Phase II BioMarCare Oncology Dx Enlivex Hadassah GvHD Hadasit ProtAb Autoimmune CellCure AMD KAHR Autoimmune Note: See slide 18 for D-Pharm clinical developments 15
Slide 16: CellCure - Using Human Embryonic Stem Cells to Cure AMD
Portfolio Company 1 CellCure - USING HUMAN EMBRYONIC STEM CELLS TO CURE AMD Our Industry and Research • AMD - The leading cause of visual impairment over the age of 55 • Currently - no reliable supply of healthy retinal cells treated only close to blindness • RPE cells derived from human Embryonic S
Slide 17: Enlivex - Inducing Immunity. For Life.
Portfolio Company 2 Enlivex - INDUCING IMMUNITY. FOR LIFE. Our Industry and Research • Graft vs. Host Disease (GvHD) - No treatment currently exists • Enlivex technology (drug and device) imitates the body’s own natural, safe way to induce tolerance Market Size/Opportunity • GvHD - $300 million • Mo
Slide 18: BioMarCare - Diagnosing Cancer with Care
Portfolio Company 3 BioMarCare - DIAGNOSING CANCER WITH CARE Our Industry and Research • Early cancer detection and monitoring • Blood/Biopsy test based kits • Novel multi-biomarker panels Market Size/Opportunity • Over $10 billion for in-vitro diagnostic tests BioMarker Progress • 3 clinical studie
Slide 19: KAHR - Drug Platform Treating Cancer and Autoimmune Diseases
Portfolio Company 4 מדיקלAUTOIMMUNE KAHR - DRUG PLATFORM TREATING CANCER; כאהר:פורטפוליו חברת DISEASES Our Industry and Research • Cancer; Autoimmune Disease • Platform technology - A new class of biological drugs • Signal Convertor Proteins (SCPs) - Fusion proteins with two functional side
Slide 20: ProtAb - Developing Treatments for Autoimmune Diseases
Portfolio Company 5 מדיקל ProtAb - DEVELOPING TREATMENTS FOR כאהר:חברת פורטפוליו AUTOIMMUNE DISEASES Our Industry and Research • Autoimmune Diseases; specifically Inflammatory Bowell Disease and Rheumatoid Arthritis • Platform technology - modulating cytokine regulation, tipping the balance t
Slide 21: D-Pharm - Innovative Drugs for Devastating Brain Disorders
Portfolio Company 6 כאהר מדיקל D-Pharm - INNOVATIVE DRUGS FOR DEVASTATING :חברת פורטפוליו BRAIN DISORDERS Our Industry and Research • Brain Disorders; i.e. Epilipsey • Utilizes lipid specific mechanisms and lipid related pathways • Vast experience and skills in GLP /GCP /GMP- compliant advanced
Slide 22: External Investments & Partners in HBL Companies
External Investments & Partners in HBL Companies TEVA Pharmaceutical Industries (NASDAQ: TEVA): $ 1 mm(2007) + $ 2 mm(2010) in Cell Cure Neurosciences + Licensing option BioTime Inc. (NYSE Amex: BTX): $ 4.1 mm(2010) in Cell Cure Neurosciences Sanofi (NYSE: SNY): $ 2 mm in KAHR Medical + Right of fir
Slide 23: Summary
Summary • The funds raised are funneled into the companies advancing the new drugs towards clinical trials • We have access to a large pipeline of innovation - Hadassah generates approx. 50 patents yearly, HBL can screen and actively investment • All companies show major progress since HBL Investmen
Slide 24: Thank You
www.hbl.co.il Thank You Ophir Shahaf CEO Hadasit Bio Holdings Ltd. Tel: +972-2-677-8757 Cell: +972-54-520-1177 Email: ophir@hbl.co.il
Hadasit Bio-Holdings — Investor Presentation (January 2013) on 6ix